BC Week In Review | May 28, 2012
Clinical News

Urocortin 2: Phase II data

The double-blind, New Zealand Phase II UNICORN trial in 53 patients with ADHF showed that IV urocortin 2 was generally well tolerated with no treatment-related serious adverse events reported. Urocortin 2 significantly reduced mean arterial...
BC Week In Review | Feb 13, 2006
Clinical News

Xerecept corticotropin releasing factor: Phase III started

NTII started the double-blind, U.S. and Canadian Phase III Acute trial in 120 patients. Patients completing the trial will have an option to continue in an open-label Phase III trial to evaluate the extended-use of...
BC Week In Review | Jan 2, 2006
Clinical News

Urocortin 2: Phase IIa data

Data from a single-blind, placebo-controlled, dose-escalation Phase IIa trial in 8 patients showed a dose-dependent increase in cardiac output of up to 40% with only a 6% increase in heart rate. Cardiac ejection fraction was...
BC Week In Review | Aug 29, 2005
Clinical News

Xerecept corticotropin releasing factor: Phase III started

NTII began an open-label, U.S. and Canadian Phase III trial to evaluate the extended use of Xerecept. The trial will enroll patients from 2 ongoing double-blind Phase III Xerecept trials, which are expected to be...
BC Week In Review | Nov 1, 2004
Clinical News

Urocortin 2: Started Phase I

NBIX began a single-blind, placebo-controlled, dose-escalating Phase I trial in 8-12 healthy volunteers. Neurocrine Biosciences Inc. (NBIX), San Diego, Calif.   Product: Urocortin 2   Business: Cardiovascular   Molecular target: Corticotropin-releasing factor ( CRF2 ) receptor  ...
BioCentury | May 3, 2004
Product Development

There's life after Namenda

The fortunes of Neurobiological Technologies Inc. have long been tied to its Namenda memantine , which is marketed for Alzheimer's disease (AD) by Forest Laboratories Inc. NTII receives a 1% royalty on those sales, but suffered...
BC Week In Review | Apr 26, 2004
Clinical News

Xerecept: Phase III started

NTII began a U.S. and Canadian Phase III trial in about 200 patients who are taking high doses of dexamethasone. NTII said it will start a second Phase III trial this summer in 120 steroid-naïve...
BC Week In Review | Nov 13, 2000
Clinical News

Neurocrine preclinical data

NBIX said that in an animal model of ischemic brain damage, its CRF1 receptor antagonists protected neurons following focal cerebral ischemia, and maintained that protection up to 1 hour after the ischemic insult. Separately, the...
Items per page:
1 - 8 of 8